Earnings summaries and quarterly performance for Owlet.
Executive leadership at Owlet.
Board of directors at Owlet.
Research analysts who have asked questions during Owlet earnings calls.
BH
Ben Haynor
Lake Street Capital Markets
3 questions for OWLT
Also covers: APYX, ATEC, BFLY +6 more
AF
Alex Fuhrman
Craig-Hallum Capital Group LLC
2 questions for OWLT
Also covers: APYX, ATER, BNED +21 more
BH
Benjamin Haynor
Lake Street Capital Markets
2 questions for OWLT
Also covers: BFLY, EKSO, IDXG +6 more
BP
Boris Peaker
Titan Partners
2 questions for OWLT
Also covers: ACOG, BLTE, GLYC +1 more
CR
Charles Rhyee
TD Cowen
2 questions for OWLT
Also covers: AMWL, BTSG, CAH +18 more
Owen Rickert
Northland Securities
2 questions for OWLT
Also covers: ASPU, BETR, HNST +3 more
Adam Chazan
TD Cowen
1 question for OWLT
LR
Lucas Romanski
BTIG
1 question for OWLT
Also covers: AMWL, DRIO, ICLR
Recent press releases and 8-K filings for OWLT.
Owlet Announces New DME Partnership with 1 Natural Way
OWLT
New Projects/Investments
Revenue Acceleration/Inflection
- Owlet, Inc. has announced a new durable medical equipment (DME) partnership with 1 Natural Way to expand insurance-supported access to its FDA-cleared prescription pulse oximeter, BabySat.
- This collaboration enables families nationwide to access BabySat through insurance-supported pathways on 1NaturalWay.com.
- The partnership aims to reach more families, including those covered by Medicaid and TRICARE, which represents approximately 9.5 million individuals within the Military Health System.
- The company expects this partnership to support continued growth in its prescription-backed revenue channel.
Dec 18, 2025, 1:45 PM
Owlet Launches Owlet360™ Subscription Service in UK and Ireland
OWLT
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Owlet, Inc. (NYSE: OWLT) has launched its new subscription service, Owlet360™, in the UK and Ireland.
- This service provides parents with personalized insights into baby health and sleep trends, leveraging Owlet's extensive infant dataset.
- Core health tracking features, including live pulse rate and oxygen level monitoring, will remain free for all users.
- Following its U.S. launch, Owlet360™ has already attracted more than 90,000 subscribers, highlighting its relevance and the durability of Owlet's recurring-revenue model.
Dec 10, 2025, 2:00 PM
Owlet Reports Record Q3 2025 Revenue and Profitability, Raises Full-Year Guidance
OWLT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Owlet reported record revenue of $32.0 million in Q3 2025, representing 44.6% year-over-year growth.
- The company achieved a gross margin of 50.6% and record adjusted EBITDA of $1.6 million in Q3 2025, marking its sixth consecutive quarter of adjusted EBITDA profitability and its first quarter with positive operating income of $1.2 million.
- Owlet updated its full-year 2025 guidance, increasing its revenue outlook to $103 million - $106 million and its adjusted EBITDA guidance to $1.25 million - $2 million.
- The company highlighted its status as the first and only FDA-Cleared Pediatric Health Monitor on the market and continued momentum with over 85,000 paying subscribers for its Owlet360 service.
Nov 13, 2025, 9:30 PM
Owlet Reports Record Q3 2025 Financial Results and Raises Full-Year Guidance
OWLT
Earnings
Guidance Update
Product Launch
- Owlet reported record Q3 2025 revenue of $32 million, a 45% increase year-over-year, and achieved its first quarterly operating profit of $1.2 million. The company also recorded a record adjusted EBITDA of $1.6 million, marking its sixth consecutive quarter of adjusted EBITDA profitability.
- Owlet's DreamSock is the first FDA-cleared over-the-counter infant monitoring device, reinforcing its market leadership, and the company launched its new DreamSight camera in September 2025.
- For the full year 2025, Owlet raised its revenue expectations to $103 million-$106 million and anticipates adjusted EBITDA of $1.25 million-$2 million, representing its first full year of adjusted EBITDA profitability. Additionally, the company completed a warrant exchange and a follow-on equity offering in October, raising approximately $32 million in net proceeds.
Nov 13, 2025, 9:30 PM
Owlet Reports Record Third Quarter 2025 Financial Results and Updates Full-Year Outlook
OWLT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Owlet, Inc. reported record Q3 2025 revenue of $32.0 million, marking a 44.6% increase from Q3 2024, alongside record Q3 net income of $4.1 million and record Q3 Adjusted EBITDA of $1.6 million.
- The company achieved a record Q3 gross profit of $16.2 million with a gross margin of 50.6%.
- Owlet's international expansion demonstrated 171% growth year-over-year, and its Owlet360 subscription service exceeded 85,000 paying subscribers.
- For the full year 2025, Owlet updated its financial outlook, expecting revenue in the range of $103 million to $106 million, representing 32% to 36% growth year-over-year, and Adjusted EBITDA between $1.25 million and $2 million.
Nov 13, 2025, 9:17 PM
Owlet Prices Public Offering of Class A Common Stock
OWLT
New Projects/Investments
- Owlet, Inc. announced the pricing of an underwritten public offering of 4,196,000 shares of its Class A common stock at $7.15 per share.
- The offering is expected to generate approximately $30.0 million in gross proceeds for Owlet, before deducting underwriting discounts and commissions and other offering expenses.
- Owlet intends to use the net proceeds from the offering to support continued commercialization and research and development, and for general corporate purposes.
- The offering is anticipated to close on or about October 23, 2025, and the underwriters have a 30-day option to purchase up to an additional 629,400 shares.
Oct 22, 2025, 4:06 AM
Owlet Receives CDSCO Approval for Infant Monitoring Devices in India
OWLT
Product Launch
New Projects/Investments
- Owlet, Inc. has secured CDSCO approval for its Dream Sock, enabling the company to launch its infant health monitoring devices in India by early 2026.
- The product suite for the Indian market will include Dream Sock, Dream Sight, Dream Duo, and the Dream App.
- India is considered a strategic growth market for Owlet, with over 23 million babies expected to be born in 2025, a rapidly evolving digital health ecosystem, and high urban smartphone penetration.
- This expansion comes despite Owlet's significant financial challenges, including a 3-year revenue decline rate of approximately -24.9% and a distressed Altman Z-Score.
Oct 15, 2025, 1:57 PM
Owlet Secures CDSCO Approval and Plans India Expansion
OWLT
Product Launch
New Projects/Investments
- Owlet, Inc. has secured CDSCO approval for its Dream Sock®, enabling its distribution in India.
- The company plans to launch its integrated monitoring devices, including Dream Sock®, Dream Sight™, and Dream Duo™, in India in early 2026.
- India represents a significant growth market, with over 23 million babies expected to be born in 2025, the highest of any country in the world.
Oct 15, 2025, 12:45 PM
Owlet Discusses Product Strategy, Market Expansion, and Financial Outlook at TD Cowen Conference
OWLT
Product Launch
Guidance Update
New Projects/Investments
- Owlet manufactures FDA-cleared wearable health monitors for babies, tracking vital signs and sleep, and is the only such monitor available to parents.
- The company is experiencing strong international growth, having doubled its business last year and expanded into 26 countries with its CE Mark-cleared device.
- Owlet has received FDA approval for BabySat, a prescription monitor, opening a new medical device channel with partnerships with six DMEs and initial reimbursement coverage from Cigna and Medicaid in 12 states.
- For the current year, Owlet provided revenue guidance of $88 million-$92 million and gross margin guidance of 50%-52%. The company anticipates future margin expansion, driven by its recently launched Owlet 360 subscription service (which has 25,000 active subscribers and 85%-90% gross margins) and the BabySat product.
Mar 5, 2025, 2:50 PM
Owlet Discusses Growth Drivers, Financial Outlook, and Strategic Initiatives
OWLT
Guidance Update
Product Launch
New Projects/Investments
- Owlet provided a revenue guidance of $88 million-$92 million and gross margin guidance of 50%-52% for the current year.
- The company is expanding its medical device, BabySat, partnering with six DMEs and focusing on 12 Medicaid states for reimbursement, with Cigna offering national commercial coverage.
- International business doubled last year, with the Dream Sock now medically cleared in 26 countries across Europe.
- The recently launched Owlet360 subscription service has 25,000 active subscribers and is expected to have 85%-90% gross margins, contributing to future margin expansion.
- Owlet plans to integrate telehealth capabilities into its app in the first half of this year and scale it towards the end of the year, leveraging its large pediatric data set.
Mar 5, 2025, 2:50 PM
Quarterly earnings call transcripts for Owlet.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more